Company, Animal health
We are pleased to announce the publication of our recent double-blind, randomised clinical trial on autologous muscle-derived mesenchymal stem cells (mdMSCs) in equine tendon and ligament injuries.
This research provides controlled clinical evidence supporting a sequential approach combining PRP (platelet-rich plasma) and autologous cell therapy, with early improvements observed in horses that do not respond sufficiently to PRP alone. This represents a significant step towards the structured, evidence-based use of orthobiologicals in equine practice.
The therapy is currently under development and registration and is being evaluated by the European Medicines Agency (EMA) for marketing authorisation. In the meantime, preventive cell banking strategies can already be considered.
We would like to thank all the researchers, collaborators and horse owners involved in this study.
#VeterinaryMedicine #RegenerativeMedicine @Equine #MSC #stemcells #orthobiologics #cellandgenetherapy